Figure 5
From: Ipilimumab augments antitumor activity of bispecific antibody-armed T cells
The pattern of dose-dependent changes in cytokine secretion levels in ATC expanded with Ipilimumab. Anti-CD3 activated T cells in PBMC derived from 3 healthy donors were cultured in the presence of 0 (control), 0.5, 5.0 and 50 μg/mL ipilimumab for 14 days. Harvested ATC were armed with EGFRBi and co-cultured with COLO356/FG target cells at 10:1 E:T for 24 hours. The supernatants were collected and quantitated in the multi-plex Luminex assay. ( a ): Shows changes in the secretion levels of CCL2, CCL3, CCL4, CCL5, CXCL9, and GM-CSF. ( b ): Shows changes in the secretion levels of IL-2R, IFN-γ, IL-12, and IL-13. Each bar represents a mean ± SE of 3 healthy donors (n = 3).